Literature DB >> 11891071

The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages.

B G Jones1, P A Dickinson, M Gumbleton, I W Kellaway.   

Abstract

Respirable poly(lactic co-glycolic acid) (PLGA) microspheres (2-3 microm diameter), were fabricated as a model drug delivery system whose uptake by macrophages could be quantified by fluorescent activated cell sorting. The microspheres exhibited minimal release of the entrapped flourophore (rhodamine B) and thus avoided possible fluid phase uptake of the flourophore. Externally bound microspheres were removed from the cell membrane by acid washing. The fluorescent intensity associated with the cells arose, therefore, from the internalised microspheres. NR8383 continuous culture alveolar macrophages were verified against primary cultures as a good model of alveolar phagocytosis. Peritoneal macrophages were also isolated and systemic and alveolar phagocytosis compared. Poloxamer 338 adsorbed at the microsphere surface did not reduce phagocytosis by NR8383 macrophages. It did, however, reduce the number of microspheres contained in primary alveolar macrophages but did not reduce the percentage of phagocytic cells. Poloxamer coatings did not reduce phagocytosis by peritoneal macrophages once the ratio of five microspheres per cell was exceeded. Dipalmitoylphosphatidylcholine (DPPC), the major component of lung surfactant, was added to cultures to model the alveolar environment where it was observed to reduce phagocytosis. In light of this finding, microspheres were coated in DPPC, which reduced their uptake by all cell types at all microsphere to cell ratios.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891071     DOI: 10.1016/s0378-5173(02)00016-9

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

Review 1.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

2.  PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B.

Authors:  Shuai Shi; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-12-19       Impact factor: 4.200

3.  The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages.

Authors:  Ming-xiu Hao; Li-sheng Jiang; Ning-yuan Fang; Jun Pu; Liu-hua Hu; Ling-Hong Shen; Wei Song; Ben He
Journal:  J Lipid Res       Date:  2010-03-20       Impact factor: 5.922

4.  Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria.

Authors:  Keiji Hirota; Keishiro Tomoda; Hiroyuki Inagawa; Chie Kohchi; Gen-Ichiro Soma; Kimiko Makino; Hiroshi Terada
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

5.  Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Ding Xu; Sherry L Kurtz; Jian Liu; Miriam Braunstein; David N McMurray; Anthony J Hickey
Journal:  Pharm Res       Date:  2007-07-27       Impact factor: 4.200

Review 6.  Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery.

Authors:  Sachin Gharse; Jennifer Fiegel
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 7.  Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy.

Authors:  Masahiro Sakagami; Peter R Byron
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  Nano-sized and micro-sized polystyrene particles affect phagocyte function.

Authors:  B Prietl; C Meindl; E Roblegg; T R Pieber; G Lanzer; E Fröhlich
Journal:  Cell Biol Toxicol       Date:  2013-11-29       Impact factor: 6.691

9.  Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.

Authors:  Samantha A Meenach; Frederick G Vogt; Kimberly W Anderson; J Zach Hilt; Ronald C McGarry; Heidi M Mansour
Journal:  Int J Nanomedicine       Date:  2013-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.